Renal osteodystrophy and secondary hyperparathyroidism

被引:29
作者
Fukagawa, M
Kazama, JJ
Kurokawa, K
机构
[1] Kobe Univ, Sch Med, Div Nephrol, Chuo Ku, Kobe, Hyogo 6500017, Japan
[2] Kobe Univ, Sch Med, Dialysis Ctr, Chuo Ku, Kobe, Hyogo 6500017, Japan
[3] Niigata Univ, Sch Med, Div Nephrol, Niigata, Japan
[4] Tokai Univ, Sch Med, Isehara, Kanagawa 25911, Japan
关键词
chronic renal failure; osteoprotegerin; PTH; RANKL; renal osteodystrophy; vitamin D;
D O I
10.1093/ndt/17.suppl_10.2
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Secondary hyperparathyroldism with marked parathyroid hyperplasia is the major type of renal osteodystrophy. In addition to classic stimuli for parathyroid hormone (PTH) such as decreased concentrations of ionized calcium and 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3, calcitriol), several mechanisms have been suggested. Those include decreased density of calcitriol and calcium-sensing receptors, as well as the direct action of phosphate. Skeletal resistance to PTH was initially recognized as a blunted calcaemic action of PTH, which has been considered another stimulus for PTH secretion. Once suppression of PTH became possible by newly developed therapeutic modalities, it has been shown that this background abnormality plays an important role in the development of adynamic bone disease in uraemic patients. However, the mechanism of skeletal resistance to PTH has not been fully elucidated yet, but recent papers suggested that osteoprotegerin (OPG) accumulating in uraemic serum might inhibit osteoclastogenesis induced by PTH.
引用
收藏
页码:2 / 5
页数:4
相关论文
共 21 条
[1]   Serum osteoprotegerin and renal osteodystrophy [J].
Coen, G ;
Ballanti, P ;
Balducci, A ;
Calabria, S ;
Fischer, MS ;
Jankovic, L ;
Manni, M ;
Morosetti, M ;
Moscaritolo, E ;
Sardella, D ;
Bonucci, E .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 (02) :233-238
[2]   DECREASED 1,25-DIHYDROXYVITAMIN-D(3) RECEPTOR DENSITY IS ASSOCIATED WITH A MORE SEVERE FORM OF PARATHYROID HYPERPLASIA IN CHRONIC UREMIC PATIENTS [J].
FUKUDA, N ;
TANAKA, H ;
TOMINAGA, Y ;
FUKAGAWA, M ;
KUROKAWA, K ;
SEINO, Y .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (03) :1436-1443
[3]   ROLE OF 1,25-DIHYDROXYVITAMIN D ON THE SKELETAL RESISTANCE TO PARATHYROID-HORMONE [J].
GALCERAN, T ;
MARTIN, KJ ;
MORRISSEY, JJ ;
SLATOPOLSKY, E .
KIDNEY INTERNATIONAL, 1987, 32 (06) :801-807
[4]   Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism [J].
Gogusev, J ;
Duchambon, P ;
Hory, B ;
Giovannini, M ;
Goureau, Y ;
Sarfati, E ;
Drueke, TB .
KIDNEY INTERNATIONAL, 1997, 51 (01) :328-336
[5]   Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients [J].
Haas, M ;
Leko-Mohr, Z ;
Roschger, P ;
Kletzmayr, J ;
Schwarz, C ;
Domenig, C ;
Zsontsich, T ;
Klaushofer, K ;
Delling, G ;
Oberbauer, R .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (03) :580-586
[6]   MECHANISMS OF DISEASE - RENAL OSTEODYSTROPHY [J].
HRUSKA, KA ;
TEITELBAUM, SL .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (03) :166-174
[7]   THE BIOLOGICAL ACTION OF CALCITRIOL IN RENAL-FAILURE [J].
HSU, CH ;
PATEL, SR ;
YOUNG, EW ;
VANHOLDER, R .
KIDNEY INTERNATIONAL, 1994, 46 (03) :605-612
[8]   Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure [J].
Kazama, JJ ;
Shigematsu, T ;
Yano, K ;
Tsuda, E ;
Miura, M ;
Iwasaki, Y ;
Kawaguchi, Y ;
Gejyo, F ;
Kurokawa, K ;
Fukagawa, M .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (03) :525-532
[9]  
Kazama Junichiro J., 2000, Journal of the American Society of Nephrology, V11, p565A
[10]  
KUROSAWA S, 1999, J PHOTOPOLYM SCI TEC, V12, P63